What is the price prediction of limn

The deep research logic is organized as follows: 

Okay, let's tackle this question about Liminatus Pharma (LIMN) stock price prediction. The user is asking for the price prediction of LIMN, and based on the provided references, I need to analyze the available data.

First, I check the references. There are several entries related to LIMN. References 1, 9, 14, 16, 18, 19, 21, and 22 mention queries about analyst price targets, average price targets, and consensus ratings. However, all these references show "0 results found" or empty data. For example, Reference 1 and 9 both have queries about analyst price targets but no results. Similarly, Reference 16 has a query about high/low price targets but only shows an empty table. This suggests that there's no available data on analyst price targets for LIMN as of the current time (2025-06-05).

Next, I look at the other references. References 5, 6, 7, and 8 discuss recent news about LIMN regaining compliance with Nasdaq listing requirements. The stock surged significantly after this news—up to 132.8% in one day. However, the company also mentioned doubts about its ability to continue as a going concern in its 10-Q filing. This indicates mixed signals: positive market reaction due to compliance but underlying financial concerns.

References 2, 3, and 4 are about analyst estimates and ratings, but they don't provide specific data—just placeholders saying "Please enable JS..." which means the actual data isn't accessible. So, no analyst ratings or estimates are available from these sources either.

Given that there are no analyst price targets or consensus ratings available, I can't provide a traditional price prediction based on analyst data. However, the recent stock surge due to compliance news and the company's pre-clinical stage in cancer therapies might indicate short-term volatility. The user's profile shows interest in short-term market movements and technical analysis, so focusing on recent price movements and market sentiment could be relevant.

I should structure the answer to highlight the lack of analyst data but mention the recent stock performance and compliance news. Also, note the company's financial concerns and the speculative nature of the stock. Since the user prefers technical analysis, maybe suggest looking at recent price trends or support/resistance levels, but without specific data, it's limited.

I need to make sure the answer is clear, starts with a conclusion, and uses the required format with tables and citations. Also, include the visualization as per the query "LIMN Analyst Average Price Target" which has 0 results. The visualization should be inserted after the relevant paragraph.

**Conclusion** 🚨
Liminatus Pharma (LIMN) lacks **analyst price targets** or **consensus ratings** as of 2025-06-05, but its stock surged 132.8% post-Nasdaq compliance news . The company’s **pre-clinical cancer therapy pipeline** and **recent regulatory clarity** could drive short-term volatility, but **sustainability risks** persist due to its “going concern” warning .

---

### 📊 **Key Data Breakdown**
| Metric | Details |
|--------|---------|
| **Recent Price Surge** | +132.8% (June 5, 2025) |
| **Nasdaq Compliance** | Regained compliance post-delayed 10-Q filing |
| **Financial Concerns** | Doubt about ability to continue as a going concern |
| **Analyst Coverage** | 0 price targets, 0 consensus ratings |

---

### 📊 **Why the Surge?**
1. **Regulatory Relief**: LIMN avoided delisting after filing its delayed 10-Q .
2. **Speculative Interest**: Biotech stocks with **pre-clinical pipelines** often see volatility .
3. **Small Float**: Only 150,000 shares available, amplifying price swings .

---

### 📊 **Risks & Outlook**
| Risk | Context |
|------|---------|
| **Financial Instability** | “Going concern” warning raises solvency doubts . |
| **Regulatory Uncertainty** | Future compliance risks could trigger volatility . |
| **Market Speculation** | High retail sentiment (extremely bullish) but no institutional backing . |

---

### 📊 **Takeaway**
LIMN’s price prediction remains **undefined** due to **zero analyst coverage**, but its **short-term upside** (132.8% surge) highlights **speculative potential**. Investors should focus on **risk management** and **real-time news** for this high-volatility stock.